You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 信達生物-B午後衝高超5% CD47/PD-L1雙抗獲批臨牀且獲增持3.47億港元
格隆匯 02-03 15:52
格隆匯2月3日丨信達生物-B(1801.HK)今日股價明顯走強,午後一度衝高超5%。現漲3.83%,報31.15港元,暫成交3861萬港元,最新總市值393.3億港元。

根據中國國家藥監局藥品審評中心(CDE)網站最新公示,信達生物開發的新型抗CD47/PD-L1雙特異性抗體IBI-322已在中國獲得臨牀試驗默示許可,適應症為實體瘤和血液腫瘤。IBI-322獲批臨牀意味着,信達生物的第三款雙特異性抗體也將邁入臨牀試驗階段。
另外,信達生物-B1月13日獲FMR LLC每股均價28.6505港元,增持1208.35萬股,總價約3.47億港元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account